May 12, 2016
4 min watch

VIDEO: Alan Taege, MD, reviews recently approved agents for HIV

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

The agents approved for HIV in recent years can be separated “into several categories,” according to Alan Taege, MD, of the Cleveland Clinic.

Taege classifies the different agents as “less new, semi-new, new and newer than new.” The “less new” drugs include the two-drug regimens Prezcobix (darunavir/cobicistat; Janssen Therapeutics) and Evotaz (atazanavir/cobicistat; Bristol-Myers Squibb). The “somewhat new” agent, Triumeq (dolutegravir/abacavir/lamivudine; ViiV Healthcare), has “very few” drug-drug interactions, according to Taege.

The “new” agent, tenofovir alafenamide (Gilead Sciences), results in lesser decreases of glomerular filtration rates and bone mineral density. “This has become an important point … because so many of our patients are now older and, thankfully, have been able to age due to good drug regimens,” Taege said.

The “newer than new” agent is an attachment inhibitor being tested in phase 3 trials, according to Taege.

“This drug is of a totally new class. The virus has never seen it before,” he said.